References

  1. Greenlee R, Hill-Harmon M, Murray T, et al. Cancer statistics. Cancer J Clin 2001; 51(1):15-36.
  2. Coleman, R. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27(3):165-176.
  3. American Cancer Society. Cancer Facts and Figures 2008. http://www.cancer.org (accessed 2/21/2008)
  4. Brown J, Cook R, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97(1):59-69.
  5. Coleman R, Major P, Lipton A, et al. Predicative value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23(22):4925-35.
  6. Van den Wyngaert T, Huizing M,Vermorken J. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol. 2007; 19(4):315-22.
  7. Lipton A, Stefer G, Figeroa J. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancerrelated bone metastases. J Clin Oncol 2007; 25(28):4431-4437.
  8. Ellis W, Pfitzenmaier J, Colli J, et al. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003; 61(2):277-281.
  9. Lang J, Hall C, Singh B, et al. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical applications? Expert Rev Anticancer Ther 2007; 7(10):1463-1472.
  10. Sales K,Winslet M, Seifalian A. Stem cells and cancer: An overview. Stem Cell Rev. 2007; [Epub ahead of print].
  11. Jones D, Nakashima T, Sanchez O, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440 (7084):692-696.
  12. Guise T, Kozlow W, Heras Herzig et al. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005; 5 Suppl(2):S46-53.
  13. Mohammad K, Guise T. Mechanisms of osteoblastic metastasis: role of endothelin-1. Clin Orthop Relat Res 2003; (415 Suppl):S67-74.
  14. Clines G, Mohammad K, Bao Y, et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007; 21(2):486-498.
  15. Wang D, Allen L, Fung E, et al. Bone scintigraphy in common tumors with osteolytic components. Clin Nucl Med 2005;30:655-71. Review.
  16. Hillner B, Ingle J, Berenson J, et al:American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in breast cancer. J Clin Oncol 2003; 21:4042-4057.
  17. Kyle R,Yee G, Somerfield, M et al.American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 Jun 10;25(17):2464-72.
  18. Lipton A,Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88(5):1082-1090.
  19. Berenson JR, Lichtenstein A, Porter L. et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16(2):593-602.
  20. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled trials. J Clin Oncol 2001; 19(2):558-567.
  21. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III double-blind comparative trial. Cancer J 2001; 7(5):377-387.
  22. Rosen, L.S., Gordon, D., Kaminski, M. et al. Long-term efficacy of zoledronic acid compared with pamidronate disodium in treatment of skeletal complications in patients with advance multiple myeloma or breast cancer: A randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98(8):1735-1744.
  23. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
  24. Rosen LS, Gordon D,Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors. A phase III, double-blind, randomized trial–The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157.
  25. Lipton A, Zheng M, and Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98:962-969.
  26. Clemons M, Dranitsaris G, Ooi W, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite firstline bisphosphonate therapy. J Clin Oncol. 2006; 20:4895-4490.
  27. Conte P and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9 (Suppl 4):28-37.
  28. Hoff AO,Toth BB, Altundag K. et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006; abstract 8528.
  29. Dimopoulos M, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increase risk after treatment with zoledronic acid. Haematologica 2006; 91(7):968-971.
  30. Ruggiero S, Gralow J, Marx R, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Practice 2006; 2(1):7-14.
  31. Coleman R. On the horizon: Can bisphosphonates prevent bone metastases? Breast. 2007 Nov 5.
  32. Santini D, Caraglia M,Vincenzi B, et al. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol. 2006; 3:325-38.
  33. Ha T, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007; 96(12):1796-801.
  34. NSABP B-34 Trial http://www.cancer.gov/clinicaltrials/NSABP-B-34 (accessed 1/28/07)
  35. Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) Trial http://clinicaltrials.gov/ct2/show/NCT00072020 (accessed 1/28/07)
  36. Aft, R,Watson, M,Ylagan, L et al. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. J. Clin Oncol 26: 2008 (May 20 suppl: abstr 1021).
  37. South Western Oncology Group (SWOG) S037 Trial http://clinicaltrials. gov (accessed 1/28/07)
  38. Burgess T, Qian T, Kaufman S, et al. Osteoprotegerin ligand (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145:527-538.
  39. Lacey D and Dunstan C. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
  40. Body J, Facon T, Coleman R, et al. A study of the biological receptor activator of nuclear factor-kB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12:1221-1228.
  41. Lipton A, Steger G, Firuero J, et al. Randomized active-controlled phase 2 study of denosumab efficacy and safety in patients with breast cancerrelated bone metastases. J Clin Oncol 2007; 25:4431-4437.
  42. Clinicaltrials.gov NCT 00399803
  43. Viotta B, Levy M, Badger A, et al. Peptide aldehyde inhibiors of cathepsin K inhibit bone resorption in vitro and in vivo. J Bone Miner Res 1997; 12:1396-1406.
  44. Stroup G, Lark M,Veber D, et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2001;16:1739-1746.
  45. Jensen AB, Olmeo N,Wynne C et al. Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial. J Clin Oncol 26: 2008 (May 20 suppl; abstr 1023).
  46. Clinical trial.gov, NCT 00170911 (accessed 1/26/07)
  47. Missbach M, Jeschke M, Feyen J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999; 24:437-439.
  48. Shakespeare W,Yang M, Bohacek R, et al. Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. PNAS 2000; 97:9373-9378.
  49. Clinical trial.gov, NCT 00410813 (accessed 1/26/07)
  50. Clinical trial.gov, NCT 00566618 (accessed 1/26/07)
  51. Clinicaltrials.gov, D8180C00034 and NCT 00558272 (accessed 5/5/08)
  52. Van't Veer L, Dai H, van de Vijver M, et al. Gene expression profiling predicts clinical outcome in breast cancer. Nature 2002; 415:530-536.
  53. Wang Y, Klijn JGM, Zhang Y et al. Gene expression profiles to predict distant metastasis of lymph node negative primary breast cancer. Lancet 2005; 365:671-679.
  54. Smid M,Wang Y, Klijn JGM et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006; 24:2261-2267.
  55. Coleman R, & Rubens R.The clinical course of bone metastases from breast cancer. British Journal of Cancer 1987; 55:61-66.
  56. Bellahcene A, Menard S, Bufalino R, et al. Expression of bone sialoprotein in human breast cancer is associated with poor survival. Int J Cancer 1996; 69:350-353.
  57. Papotti M, Kalebic T,Volante M, et al. Bone sialoprotein is predictive of bone metastases in resectable non-small cell lung cancer: a retrospective case-control study. J Clin Oncol 2006; 24:4818-4824.
  58. Hillner B. Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin Oncol 2001; 28(Suppl 11): 64-68.
  59. Delea T, Langer C, McKiernan J, et al.The cost of treatment of skeletalrelated events in patients with bone metastases from lung cancer. Oncology 2004; 67:390-396.
  60. Brown J,Thomson C, Ellis S, Gutcher S, Purohit O, Coleman R. Bone resorption predicts for skeletal complications in metastatic bone disease. British Journal of Cancer 2003; 89:2031-2037.
  61. Coleman R, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clinical Oncology 2005; 23:4925-4935.
  62. Brown J, Cook R, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. National Cancer Institute 2005; 97:59-69.
  63. ATAC Trialists' Group. Results of the ATAC (Arimidex,Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
  64. Coates A, Keshaviah A,Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486-492.
  65. Coombes R, Kilburn L, Snowdon C, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559-570.
  66. Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching postmenopausal women with hormone sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
  67. Goss P, Ingle J, Martino S, et al. Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-1271.
  68. Cummings S, Browner W, Bauer D et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339: 33-738.
  69. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25:820-828.
  70. Bundred N, Campbell I, Coleman R, et al. Zoledronic acid in the prevention of cancer treatment induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer. Cancer 2008; 112:1001-10.
  71. Eastell R, Adams J, Coleman R, et al. Effect of anastrozole on bone mineral density: 5-year results from the ATAC Trial (18233230). J Clin Oncol 2008; 26:1051-57.
  72. Kanis J, Oden A, Johnell O, et al.The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporosis Int. 2007; 18:1033-1046.
  73. Brufsky A, Harker W, Beck J, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25:829-836.
  74. Lester J, Gutcher S, Ellis S, et al. Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. J Clin Oncol 2007: 25: Abstract 553.
  75. Eastell R, van Poznack C, Hannon RA et al.The SABRE (Study of anastrozole with the bisphosphonate risedronate) Study: 12 month analysis. JBMR 2007: 22(suppl 1): Abstract 300.
  76. Allain TJ. Prostate cancer, osteoporosis and fracture risk. Gerentology 2006; 52: 107-110.
  77. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001; 345(13):948-55.
  78. Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169:2008- 2012.

^ Back to top